Hospital Universitario Marqués de Valdecilla -ko ikertzaileekin lankidetzan egindako argitalpenak (70)

2024

  1. Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))

    Autoimmunity Reviews

  2. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  3. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel

    Autoimmunity Reviews, Vol. 22, Núm. 12

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 18, Núm. 1, pp. 33-41

  3. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

    RMD Open, Vol. 8, Núm. 2

  4. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy

    Clinical and experimental rheumatology, Vol. 40, Núm. 5, pp. 988-992

  5. TNF Inhibitors Exert a “Hidden” Beneficial Effect in the Cardiovascular Lipoprotein Profile of RA Patients

    Biologics: Targets and Therapy, Vol. 16, pp. 187-197

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  2. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

  3. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

  4. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  2. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  3. Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey

    Autoimmunity Highlights, Vol. 11, Núm. 1

  4. Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377

  5. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)

    Lupus, Vol. 29, Núm. 1, pp. 27-36

  6. Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review

    Reumatologia Clinica, Vol. 16, Núm. 3, pp. 222-228